Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

• Published in: Respiratory research 2010-10, Vol.11 (1), p.137-137, Article 137
• Main Authors: VanDevanter, Donald R, O'Riordan, Mary A, Blumer, Jeffrey L, Konstan, Michael W
• Format: Article
• Language: English
• Subjects: Acute Disease; Analysis; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibacterial agents; Antibiotics; Bacterial diseases; Bacterial infections; Ceftazidime; Chronic infection; Cystic fibrosis; Cystic Fibrosis - drug therapy; Cystic Fibrosis - physiopathology; Data processing; Disease Progression; Diseases; Drug therapy; Forced Expiratory Volume - drug effects; Forced Expiratory Volume - physiology; Health aspects; Humans; Infection; Infections; Inflammation; Intravenous administration; Lung diseases; Meropenem; Morbidity; Pseudomonas aeruginosa; Resource utilization; Respiratory function; Respiratory Function Tests; Retrospective Studies; Time Factors; Tobramycin; Treatment Outcome
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/1465-9921-11-137

Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of lung function linked to inflammation due to chronic bacterial infection (principally Pseudomonas aeruginosa). Pulmonary exacerbations (intermittent episodes during which symptoms of lung infection increase and lung function decreases) can cause substantial resource utilization, morbidity, and irreversible loss of lung function. Intravenous antibiotic treatment to reduce exacerbation symptoms is standard management practice. However, no prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has been identified as an area of concern and interest. We have retrospectively analyzed pulmonary function response data (as forced expiratory volume in one second; FEV1) from a previous blinded controlled CF exacerbation management study of intravenous ceftazidime/tobramycin and meropenem/tobramycin in which spirometry was conducted daily to assess the time course of pulmonary function response. Ninety-five patients in the study received antibiotics for at least 4 days and were included in our analyses. Patients received antibiotics for an average of 12.6 days (median = 13, SD = 3.2 days), with a range of 4 to 27 days. No significant differences were observed in mean or median treatment durations as functions of either treatment group or baseline lung disease stage. Average time from initiation of antibiotic treatment to highest observed FEV1 was 8.7 days (median = 10, SD = 4.0 days), with a range of zero to 19 days. Patients were treated an average of 3.9 days beyond the day of peak FEV1 (median = 3, SD = 3.8 days), with 89 patients (93.7%) experiencing their peak FEV1 improvement within 13 days. There were no differences in mean or median times to peak FEV1 as a function of treatment group, although the magnitude of FEV1 improvement differed between groups. Our results suggest that antibiotic response to exacerbation as assessed by pulmonary function is essentially complete within 2 weeks of treatment initiation and relatively independent of the magnitude of pulmonary function response observed.